---
title: "This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zone"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295139243.md"
description: "Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike."
datetime: "2026-08-06T20:21:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295139243.md)
  - [en](https://longbridge.com/en/news/295139243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295139243.md)
generator: "portal-rs"
---

# This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zone

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

### Related Stocks

- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296673080.md)
- [$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296632631.md)
- [97,573 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Rice Hall James & Associates LLC](https://longbridge.com/en/news/296209446.md)
- [Travere Therapeutics director Gary A. Lyons disposes of USD 629,150 in common shares](https://longbridge.com/en/news/296394692.md)
- [Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum](https://longbridge.com/en/news/296303022.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**